Cosette G. Schneider

Cosette G. Schneider

Auto-generated profile, based on publicly available information

Cosette G. Schneider

Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2021 in npj Vaccines
Verified
Journal Article
Open access
PDF file
KMKatherine L. Mallory
Katherine L. Mallory
JTJustin A. Taylor
Justin A. Taylor
XZXiaoyan Zou
Xiaoyan Zou
IWIshita N. Waghela
Ishita N. Waghela
CSCosette G. Schneider
Cosette G. Schneider
EAEvelina Angov
Evelina Angov
Human malaria affects the vast majority of the world’s population with the Plasmodium falciparum species causing the highest rates of morbidity and mortality. With no licensed vaccine and leading candidates achieving suboptimal protection in the field, the need for an effective immunoprophylactic option continues to motivate the malaria research community to explore alternative technologies. Recent advances in the mRNA discipline have elevated the long-neglected platform to the forefront of infectious disease research. As the immunodominant coat protein of the invasive stage of the malaria parasite, circumsporozoite protein (PfCSP) was selected as the antigen of choice to assess the immunogenic and protective potential of an mRNA malaria vaccine. In mammalian cell transfection experiments, PfCSP mRNA was well expressed and cell associated. In the transition to an in vivo murine model, lipid nanoparticle (LNP) encapsulation was applied to protect and deliver the mRNA to the cell translation machinery and supply adjuvant activity. The immunogenic effect of an array of factors was explored, such as formulation, dose, number, and interval of immunizations. PfCSP mRNA-LNP achieved sterile protection against infection with two P. berghei PfCSP transgenic parasite strains, with mRNA dose and vaccination interval having a greater effect on outcome. This investigation serves as the assessment of pre-erythrocytic malaria, PfCSP mRNA vaccine candidate resulting in sterile protection, with numerous factors affecting protective efficacy, making it a compelling candidate for further investigation.

29 January 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
CSCosette G. Schneider
Cosette G. Schneider
JTJustin A. Taylor
Justin A. Taylor
MSMichael Q. Sibilo
Michael Q. Sibilo
KMKazutoyo Miura
Kazutoyo Miura
KMKatherine L. Mallory
Katherine L. Mallory
EAEvelina Angov
Evelina Angov
Self-assembling protein nanoparticles (SAPN) serve as a repetitive antigen delivery platform with high-density epitope display; however, antigen characteristics such as size and epitope presentation can influence the immunogenicity of the assembled particle and are aspects to consider for a rationally designed effective vaccine. Here, we characterize the folding and immunogenicity of heterogeneous antigen display by integrating (a) dual-stage antigen SAPN presenting the P. falciparum (Pf) merozoite surface protein 1 subunit, PfMSP119, and Pf cell-traversal protein for ookinetes and sporozoites, PfCelTOS, in addition to (b) a homogenous antigen SAPN displaying two copies of PfCelTOS. Mice and rabbits were utilized to evaluate antigen-specific humoral and cellular induction as well as functional antibodies via growth inhibition of the blood-stage parasite. We demonstrate that antigen orientation and folding influence the elicited immune response, and when appropriately designed, SAPN can serve as an adaptable platform for an effective multi-antigen display.

10 June 2022 in Vaccine
Verified
Journal Article
Open access
CSCosette G. Schneider
Cosette G. Schneider
JFJulien Fey
Julien Fey
XZXiaoyan Zou
Xiaoyan Zou
VGVince Gerbasi
Vince Gerbasi
TSTatyana Savransky
Tatyana Savransky
EAEvelina Angov
Evelina Angov
Despite the development of prophylactic anti-malarial drugs and practices to prevent infection, malaria remains a health concern. Preclinical testing of novel malaria vaccine strategies achieved through rational antigen selection and novel particle-based delivery platforms is yielding encouraging results. One such platform, self-assembling virus-like particles (VLP) is safer than attenuated live viruses, and has been approved as a vaccination tool by the FDA. We explore the use of Norovirus sub-viral particles lacking the natural shell (S) domain forming the interior shell but that retain the protruding (P) structures of the native virus as a vaccine vector. Epitope selection and their surface display has the potential to focus antigen specific immune responses to crucial epitopes. Recombinant P-particles displaying epitopes from two malaria antigens, Plasmodium falciparum (Pf) CelTOS and Plasmodium falciparum (Pf) CSP, were evaluated for immunogenicity and their ability to confer protection in a murine challenge model. Immune responses induced in mice resulted either in sterile protection (displaying PfCelTOS epitopes) or in antibodies with functional activity against sporozoites (displaying PfCSP epitopes) in an in vitro liver-stage development assay (ILSDA). These results are encouraging and support further evaluation of this platform as a vaccine delivery system.

17 May 2023 in Molecular Therapy
Verified
Journal Article
Open access
CSCosette Schneider
Cosette Schneider
LCLynda Coughlan
Lynda Coughlan

1 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
SCSabal Chaulagain
Sabal Chaulagain
AWAnnie Werner
Annie Werner
MPMaclaine A. Parish
Maclaine A. Parish
STSattya Narayan Talukdar
Sattya Narayan Talukdar
BSBrittany A. Seibert
Brittany A. Seibert
SKSabra Klein
Sabra Klein
H5N1 vaccines have been poorly immunogenic in humans, creating a challenge for vaccine development. Seasonal influenza vaccines offer some cross-protection against H5N1, but there has been no consideration of whether protection differs between the sexes. We investigated antibody responses and protection in adult male and female C57BL/6 mice following vaccination with either beta-propiolactone inactivated whole virus H1N1 or H5N1 (LAIV backbone) vaccines. Using systems serology assays, we uncovered that vaccination induced strong homologous antibody responses, with females generating greater total IgG than males against both H1N1 and H5N1, which was primarily mediated by greater IgG responses to neuraminidase (NA) than hemagglutinin (HA) protein. Cross-reactive H1N1 IgG titers were greater among H5N1-vaccinated females, primarily mediated by greater N1-specific IgG titers. IgG2b and IgG2c were the primary antibody isotypes generated in response to these vaccines, with females having greater IgG2b titers and enhanced binding to FcγRIV for avian and human NA than males following either homologous or heterologous vaccination. Antibody-dependent complement deposition was measured as an FcR-mediated non-neutralizing response against HA and NA and was robust in both sexes. Vaccinated females had greater neutralizing antibody titers than males against the homologous vaccine strain, with limited cross-neutralizing antibodies detected in either sexes. Neuraminidase inhibition titers were greater in vaccinated females than males against the heterologous virus following H1N1 vaccination and against both the vaccine and heterologous viruses following H5N1 vaccination. When H1N1 and H5N1 vaccinated mice were challenged with a lethal dose of A/Texas/37/2024 H5N1, all H5N1 vaccinated mice were protected, regardless of sex. Among H1N1 vaccinated mice, while both sexes were protected against disease, H1N1 vaccinated females cleared virus faster than their male counterparts. These findings highlight that female-biased NA-specific antibodies result in greater cross-protection and should be considered in studies of influenza vaccines.

21 August 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
BSBrittany A. Seibert
Brittany A. Seibert
MPMaclaine A. Parish
Maclaine A. Parish
STSattya N. Talukdar
Sattya N. Talukdar
TZTianle Zhang
Tianle Zhang
JLJennifer A. Liu
Jennifer A. Liu
SKSabra L. Klein
Sabra L. Klein
Avian influenza H5N1 has pandemic potential and historically causes more severe disease in pregnant women than the general population. With increasing transmission of H5N1 detected among placental mammals, animal models are necessary for testing countermeasures, including during pregnancy. Pregnant outbred mice infected with a contemporary strain of bovine H5N1 during the second trimester equivalent causes in utero transmission, with infectious virus detected in the uterus, placenta, and fetus. Birth following third trimester infection results in offspring with decreased size, neurodevelopmental delays, and adolescent behavioral impairments, with infectious virus detected in the neonatal milk ring and lungs, as well as mammary tissues. H5N1 viral protein colocalizes with trophoblast cells in the placenta and epithelial cells in mammary tissue that spatially overlap with lectins for α2,3-linked SA. With the pandemic potential of H5N1, our vertical transmission model in placental mammals is essential for understanding viral spread and evaluating treatments during pregnancy.